Back to top

Image: Bigstock

Jazz Pharmaceuticals Public Limited Company

Read MoreHide Full Article

Jazz reported better-than-expected earnings in Q3 while revenue fell short of the estimate. Jazz’s sleep disorder drug Xyrem is the only FDA approved product for both cataplexy and EDS. Its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. In October, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos and plans to finish it in early 2017. We believe Vyxeos has multi-million dollar potential.  However, Xyrem, is facing patent challenges and some of Xyrem’s patents are undergoing inter partes review. Jazz has also been facing challenges in building sufficient inventory levels for Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions in certain markets, including the U.S., from time to time.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Jazz Pharmaceuticals PLC (JAZZ) - free report >>